Evidence map›Paper›PMID 40925125›Full record

ArticleRedox biology2025

Carbon ion combined photon radiotherapy induces ferroptosis via NCOA4-mediated ferritinophagy in glioblastoma.

Li Chen, Wanzun Lin, Ziyu Le, Fangzhu Wan, Haojiong Zhang, Shikai Geng, Qingting Huang, Jing Gao, Wei Hu, Huaiyuan Chen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Redox biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. BZW1 Drives Immune Evasion in Lung Adenocarcinoma via Ferroptosis Suppression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  5. AgJournal of nanobiotechnology · 2026
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Li ChenDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China.
Wanzun LinDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China.
Ziyu LeDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China.
Fangzhu WanDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China.
Haojiong ZhangShanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China; Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, 201321, China.
Shikai GengDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China.
Qingting HuangShanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China; Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, 201321, China.
Jing GaoShanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China; Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, 201321, China.
Wei HuDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China.
Huaiyuan ChenDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China.
Xingyu LiuDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China.
Chunlin ShaoShanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China; Department of Research and Development, Shanghai Proton and Heavy lon Center, Fudan University Cancer Hospital, Shanghai, 201315. China; Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai, China.
Fengtao SuShanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China; Department of Research and Development, Shanghai Proton and Heavy lon Center, Fudan University Cancer Hospital, Shanghai, 201315. China; Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai Medical College of Fudan University, Shanghai, China.
Jiade J LuDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China.
Lin KongDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China; Shanghai Key Laboratory of Radiation Oncology, Shanghai, 201321, China; Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201321, China. Electronic address: linkong1152@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM), the most prevalent and lethal primary malignancy of the central nervous system, remains refractory to conventional photon radiotherapy due to inherent limitations in dose distribution. Although carbon ion radiotherapy offers distinct advantages, including its characteristic Bragg peak deposition and superior relative biological effectiveness, its clinical application is constrained by high costs and increased toxicity. This study explores the radiobiological interactions underlying a mixed carbon ion-photon irradiation regimen, a promising strategy in advanced particle therapy. Our findings demonstrate that combined irradiation exerts synergistic cytotoxic effects in GBM models. Mechanistic analysis reveals that this combination induces clustered DNA double-strand breaks, leading to the cytoplasmic accumulation of double-stranded DNA (dsDNA) fragments. This, in turn, activates the cGAS-STING-mediated cytosolic DNA sensing pathway, which facilitates NCOA4-FTH1 axis-driven ferritinophagy and ultimately triggering iron-dependent ferroptosis. These findings offer a new mechanistic perspective on optimizing combined particle therapy regimens for GBM treatment, with significant implications for translational applications in clinical radiation oncology.

Indexed as

Brain NeoplasmsFerritinsFerroptosisGlioblastomaHeavy Ion RadiotherapyNuclear Receptor CoactivatorsPhotonsAnimalsAutophagyCell Line, TumorHumansMiceFerritinsNCOA4 protein, humanNuclear Receptor CoactivatorsCarbon ion radiotherapyFerritinophagyFerroptosisGlioblastomaPhoton radiotherapy

Identifiers

PMID40925125
PMCPMC12450722

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.